CalciMedica is a clinical-stage biotechnology company focused on discovery and development of small-molecule CRAC channel inhibitors to treat severe acute and chronic inflammatory diseases. Its lead product, Auxora, has data from a Phase 2a acute pancreatitis trial and a Phase 2 COVID-19 pneumonia trial suggesting prevention of organ tissue damage and rapid restoration of organ function. Auxora is currently being evaluated in a blinded, placebo-controlled trial in severe and critical COVID-19 pneumonia (up to 400 patients planned; over 200 randomized to date) and a Phase 2b trial in acute pancreatitis is set to start enrolling in the coming weeks. The company plans to use proceeds from the Series D financing to advance clinical development across Auxora and its broader CRAC inhibitor portfolio. CalciMedica is privately held and headquartered in San Diego, California, and the announced financing will be completed in multiple private closings. The financing also included board augmentation with Zafi Avnur, Ph.D., of Quark Venture joining the board, indicating investor operational involvement. CalciMedica is a La Jolla, California-based clinical-stage biotechnology company focused on discovery and development of drugs that target calcium release-activated calcium (CRAC) channels for treatment of acute and chronic inflammatory diseases. The company is advancing Auxora (formerly CM4620-IE), a potent and selective small-molecule CRAC channel inhibitor that prevents CRAC channel overactivation. CRAC channels control the entry of calcium into immune and other cell types, and CalciMedica says modulating this pathway can reduce detrimental calcium signaling in inflammatory conditions. The company intends to use the new funding to advance ongoing clinical trials evaluating Auxora in patients with COVID-19 pneumonia requiring oxygen therapy and to accelerate commercial manufacturing for the drug. CalciMedica is led by CEO Rachel Leheny, Ph.D. In May 2020 the company raised $15M in a Series C financing led by Valence Life Sciences with participation from Bering Capital, Mesa Verde Venture Partners and existing investor Sanderling Ventures. CalciMedica is developing selective CRAC channel inhibitors intended to treat inflammatory and autoimmune diseases. Over the past year the company reported significant progress identifying and characterizing CRAC channel inhibitors with attractive pharmaceutical properties. Management states these candidates have the potential to become safe and effective drugs for inflammatory and autoimmune indications. Financially, CalciMedica closed the second tranche of a $12M Series C financing and has raised a total of $19M in equity funding to date. Prior financings include a seed round from SR One in December 2006 and a Series B in August 2007. The Series C round included participation from BiogenIdec New Ventures, Sanderling Ventures and SR One. CalciMedica is a San Diego-based biotechnology company focused on autoimmune and inflammatory disease. The reporting states the company raised $1.53 million in its first funding round. The funding was provided by S.R. One, according to a regulatory filing cited by PE Hub. The articles do not disclose specific product candidates, pipeline details, or operating metrics such as revenue or user numbers. No future plans or use of proceeds were detailed in the coverage. The public reporting is limited to the amount raised, the investor, and the regulatory filing citation.

Total raised

$38M

Funding rounds

4

Latest round

Series D

Latest activity

Mar 2021